The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.
Jean-Marie Michot, MD
Advertisement
Articles by Jean-Marie Michot, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Nivolumab-AVD in Classical Hodgkin Lymphoma
2
Sacituzumab Govitecan Improves QOL in Untreated Advanced TNBC
3
T-DXd Benefit Consistent Across Subgroups in High-Risk HER2+ Breast Cancer
4
Abemaciclib Monotherapy Shows Clinical Benefit Post-CDK4/6 Inhibitor Progression in HR+/HER2– mBC
5
